8 known cases. View patent page →
Regeneron secured a district court victory finding Mylan infringed US Patent 11084865. A subsequent settlement between Regeneron and Biocon (Mylan's associate) led to the dismissal of the district court case and a related Federal Circuit appeal (CAFC Appeal No. 24-2002), allowing commercialization of Mylan's biosimilar in 2026.
Regeneron sued Samsung Bioepis for infringement of US Patent 11084865. The district court granted a preliminary injunction, which the Federal Circuit affirmed. A related IPR challenge (IPR2025-00176) at the PTAB was denied institution.
Regeneron sued Formycon for infringement of US Patent 11084865. The district court granted a preliminary injunction, which the Federal Circuit affirmed. A related IPR challenge (IPR2025-00233) at the PTAB was denied institution.
Regeneron sued Celltrion for infringement of US Patent 11084865. The district court granted a preliminary injunction, which the Federal Circuit affirmed. A related IPR challenge (IPR2025-00456) at the PTAB was denied institution.
Regeneron sued Amgen for infringement of US Patent 11084865. The district court denied Regeneron's preliminary injunction request, a decision upheld by the Federal Circuit (CAFC Appeal No. 24-2351), leading Amgen to launch its biosimilar at-risk.
Regeneron initiated litigation against Sandoz concerning US Patent 11084865. The case is ongoing, following the approval of Sandoz's biosimilar in August 2024.
Fresenius Kabi SwissBioSim filed an IPR petition against US Patent 11084865 owned by Regeneron Pharmaceuticals, Inc., but the PTAB denied institution on procedural grounds.
A patent litigation case involving US Patent 11084865 was filed under case number 3:24-cv-08760 in the New Jersey District Court, but further details on parties or status are not provided.